
|Articles|July 1, 2002
Anti-VEGF therapy holds promise for CNV in AMD
Author(s)Laszlo Dosa
Fort Lauderdale, FL-Anti-vascular endothelial growth factor (anti-VEGF) therapy is a promising treatment of neovascularization brought on by various ocular diseases, including age-related macular degeneration (AMD), according to Lawrence J. Singerman, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025 Takeaways: The new era of glaucoma treatment and surgical precision
2
AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives
3
Managing Unique Dry Eye Disease Subtypes in Patients
4
AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081
5

















































.png)


